Cargando…

522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital

BACKGROUND: Ceftazidime/avibactam (CZA) and ceftolozane-tazobactam (CT) are new additions to the antibiotic armamentarium with activity against gram-negative pathogens, most notably drug-resistant Pseudomonas aeruginosa (PSA). The purpose of this study was to compare the in vitro activity of CZA and...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Twisha S, Kaye, Keith S, Marshall, Vince, Krishnan, Jay, Mills, John, Albin, Owen, Smith, Aaron, Young, Carol, Lephart, Paul, Pogue, Jason M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811331/
http://dx.doi.org/10.1093/ofid/ofz360.591
_version_ 1783462459051343872
author Patel, Twisha S
Kaye, Keith S
Marshall, Vince
Krishnan, Jay
Mills, John
Albin, Owen
Smith, Aaron
Young, Carol
Lephart, Paul
Pogue, Jason M
author_facet Patel, Twisha S
Kaye, Keith S
Marshall, Vince
Krishnan, Jay
Mills, John
Albin, Owen
Smith, Aaron
Young, Carol
Lephart, Paul
Pogue, Jason M
author_sort Patel, Twisha S
collection PubMed
description BACKGROUND: Ceftazidime/avibactam (CZA) and ceftolozane-tazobactam (CT) are new additions to the antibiotic armamentarium with activity against gram-negative pathogens, most notably drug-resistant Pseudomonas aeruginosa (PSA). The purpose of this study was to compare the in vitro activity of CZA and CT against a large real-world sample of clinical isolates of PSA displaying different phenotypes of resistance to conventional β-lactams at an institution where both CZA and CT are routinely tested on all isolates. METHODS: All cultures from patient infections with PSA from May 2018 to February 2019 at Michigan Medicine were included. Minimum inhibitory concentrations (MICs) for all β-lactams were determined using TREK broth microdilution panels and isolates were considered susceptible to CZA if the MIC was ≤8 mg/L and CT if the MIC was ≤4 mg/L. RESULTS: A total of 2,972 isolates of PSA from clinical specimens were included. Table 1 compares CZA and CT susceptibility, MIC(50), MIC(90), and MIC range for all isolates including those displaying resistance to various β-lactams. Among all isolates of PSA, CZA (96.2% susceptible) was slightly more active than CT (94.2%) and both agents were ~10% more active than the closest comparator (ceftazidime, 86.6%). In vitro activity of cefepime, piperacillin/tazobactam, and meropenem were 84.8%, 78%, and 80.3%, respectively. The activity of both CZA and CT dropped significantly among isolates with pan-β-lactam resistance (i.e., resistance to all conventional anti-pseudomonal β lactams, PBR) but CZA remained more active than CT (59.4% vs. 41.5%, P < 0.001). Of isolates displaying resistance to CT, 84 (48.6%) were susceptible to CZA. However, of those with resistance to CZA, only 24 (21.2%) were susceptible to CT (Table 2). CONCLUSION: CZA was the most active β-lactam against PSA isolates at Michigan Medicine. Among PSA with PBR, CZA demonstrated superior activity compared with CT. Additionally, a significant number of isolates with resistance to CT were susceptible to CZA. Our findings are unique compared with other published reports where CT has consistently demonstrated greater activity than CZA against resistant P. aeruginosa and suggest routine testing of both CT and CZA should occur. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811331
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68113312019-10-28 522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital Patel, Twisha S Kaye, Keith S Marshall, Vince Krishnan, Jay Mills, John Albin, Owen Smith, Aaron Young, Carol Lephart, Paul Pogue, Jason M Open Forum Infect Dis Abstracts BACKGROUND: Ceftazidime/avibactam (CZA) and ceftolozane-tazobactam (CT) are new additions to the antibiotic armamentarium with activity against gram-negative pathogens, most notably drug-resistant Pseudomonas aeruginosa (PSA). The purpose of this study was to compare the in vitro activity of CZA and CT against a large real-world sample of clinical isolates of PSA displaying different phenotypes of resistance to conventional β-lactams at an institution where both CZA and CT are routinely tested on all isolates. METHODS: All cultures from patient infections with PSA from May 2018 to February 2019 at Michigan Medicine were included. Minimum inhibitory concentrations (MICs) for all β-lactams were determined using TREK broth microdilution panels and isolates were considered susceptible to CZA if the MIC was ≤8 mg/L and CT if the MIC was ≤4 mg/L. RESULTS: A total of 2,972 isolates of PSA from clinical specimens were included. Table 1 compares CZA and CT susceptibility, MIC(50), MIC(90), and MIC range for all isolates including those displaying resistance to various β-lactams. Among all isolates of PSA, CZA (96.2% susceptible) was slightly more active than CT (94.2%) and both agents were ~10% more active than the closest comparator (ceftazidime, 86.6%). In vitro activity of cefepime, piperacillin/tazobactam, and meropenem were 84.8%, 78%, and 80.3%, respectively. The activity of both CZA and CT dropped significantly among isolates with pan-β-lactam resistance (i.e., resistance to all conventional anti-pseudomonal β lactams, PBR) but CZA remained more active than CT (59.4% vs. 41.5%, P < 0.001). Of isolates displaying resistance to CT, 84 (48.6%) were susceptible to CZA. However, of those with resistance to CZA, only 24 (21.2%) were susceptible to CT (Table 2). CONCLUSION: CZA was the most active β-lactam against PSA isolates at Michigan Medicine. Among PSA with PBR, CZA demonstrated superior activity compared with CT. Additionally, a significant number of isolates with resistance to CT were susceptible to CZA. Our findings are unique compared with other published reports where CT has consistently demonstrated greater activity than CZA against resistant P. aeruginosa and suggest routine testing of both CT and CZA should occur. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811331/ http://dx.doi.org/10.1093/ofid/ofz360.591 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Patel, Twisha S
Kaye, Keith S
Marshall, Vince
Krishnan, Jay
Mills, John
Albin, Owen
Smith, Aaron
Young, Carol
Lephart, Paul
Pogue, Jason M
522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
title 522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
title_full 522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
title_fullStr 522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
title_full_unstemmed 522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
title_short 522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
title_sort 522. in vitro antimicrobial activity of ceftazidime/avibactam compared with ceftolozane/tazobactam against real-world clinical isolates of pseudomonas aeruginosa at a large academic tertiary care hospital
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811331/
http://dx.doi.org/10.1093/ofid/ofz360.591
work_keys_str_mv AT pateltwishas 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT kayekeiths 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT marshallvince 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT krishnanjay 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT millsjohn 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT albinowen 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT smithaaron 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT youngcarol 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT lephartpaul 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital
AT poguejasonm 522invitroantimicrobialactivityofceftazidimeavibactamcomparedwithceftolozanetazobactamagainstrealworldclinicalisolatesofpseudomonasaeruginosaatalargeacademictertiarycarehospital